Icure Pharmaceutical Incorporation Statistics

Total Valuation

Icure Pharmaceutical Incorporation has a market cap or net worth of KRW 76.98 billion. The enterprise value is 145.05 billion.

Market Cap	76.98B
Enterprise Value	145.05B

Important Dates

The last earnings date was Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Icure Pharmaceutical Incorporation has 37.37 million shares outstanding. The number of shares has increased by 22.15% in one year.

Current Share Class	n/a
Shares Outstanding	37.37M
Shares Change (YoY)	+22.15%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	15.21%
Owned by Institutions (%)	0.41%
Float	31.69M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.29
PB Ratio	1.45
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.07
EV / Sales	2.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.18

Financial Position

The company has a current ratio of 0.35, with a Debt / Equity ratio of 1.41.

Current Ratio	0.35
Quick Ratio	0.18
Debt / Equity	1.41
Debt / EBITDA	n/a
Debt / FCF	-4.82
Interest Coverage	-4.32

Financial Efficiency

Return on equity (ROE) is -37.46% and return on invested capital (ROIC) is -10.96%.

Return on Equity (ROE)	-37.46%
Return on Assets (ROA)	-9.20%
Return on Capital (ROIC)	-10.96%
Revenue Per Employee	279.64M
Profits Per Employee	-111.62M
Employee Count	214
Asset Turnover	0.36
Inventory Turnover	4.57

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +8.54% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+8.54%
50-Day Moving Average	2,102.42
200-Day Moving Average	2,230.81
Relative Strength Index (RSI)	44.76
Average Volume (20 Days)	1,421,706

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Icure Pharmaceutical Incorporation had revenue of KRW 59.84 billion and -23.89 billion in losses. Loss per share was -637.81.

Revenue	59.84B
Gross Profit	4.99B
Operating Income	-24.74B
Pretax Income	-25.04B
Net Income	-23.89B
EBITDA	-15.82B
EBIT	-24.74B
Loss Per Share	-637.81

Full Income Statement

Balance Sheet

The company has 9.02 billion in cash and 76.16 billion in debt, giving a net cash position of -67.14 billion or -1,796.73 per share.

Cash & Cash Equivalents	9.02B
Total Debt	76.16B
Net Cash	-67.14B
Net Cash Per Share	-1,796.73
Equity (Book Value)	53.84B
Book Value Per Share	1,415.83
Working Capital	-60.19B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -14.68 billion and capital expenditures -1.12 billion, giving a free cash flow of -15.80 billion.

Operating Cash Flow	-14.68B
Capital Expenditures	-1.12B
Free Cash Flow	-15.80B
FCF Per Share	-422.93

Full Cash Flow Statement

Margins

Gross margin is 8.34%, with operating and profit margins of -41.34% and -39.92%.

Gross Margin	8.34%
Operating Margin	-41.34%
Pretax Margin	-41.85%
Profit Margin	-39.92%
EBITDA Margin	-26.43%
EBIT Margin	-41.34%
FCF Margin	-26.41%

Dividends & Yields

Icure Pharmaceutical Incorporation does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.15%
Shareholder Yield	-22.15%
Earnings Yield	-30.96%
FCF Yield	-20.53%

Stock Splits

The last stock split was on December 14, 2022. It was a forward split with a ratio of 1.2.

Last Split Date	Dec 14, 2022
Split Type	Forward
Split Ratio	1.2

Scores

Icure Pharmaceutical Incorporation has an Altman Z-Score of -0.98. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.98
Piotroski F-Score	n/a